

**05/02/2022**

## **Second COVID-19 Vaccine Booster Dose Update**

### **Background:**

On March 29, 2022, the U.S. Food and Drug Administration (FDA) amended the emergency use authorization (EUA) for the Pfizer-BioNTech and Moderna COVID-19 vaccine as follows:

- Authorization of a second booster dose for individuals 50 years and older at least 4 months after the first booster dose with any authorized or approved COVID-19 vaccine.
- Immunocompromised individuals may receive a second booster at least 4 months after the first booster dose with any authorized or approved COVID-19 vaccine subject to the age-specific limitations for the respective vaccine.
  - o The Pfizer-BioNTech COVID-19 vaccine is indicated for individuals 12 years and older.
  - o The Moderna COVID-19 vaccine is indicated for individuals 18 years and older.

### **Key Details:**

HHSC allows for pharmacy benefit coverage of the Pfizer-BioNTech and Moderna COVID-19 vaccine in compliance with the expanded use authorized by the FDA. MCOs must work with their pharmacy benefit managers to modify their systems if necessary to allow coverage for booster doses of the Pfizer-BioNTech and Moderna COVID-19 vaccine, given the updated EUA issued by the FDA. HHSC continues to cover the administration of the Pfizer-BioNTech and Moderna COVID-19 vaccine based on the Medicare rate for vaccine administration as non-risk.